Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug

Chengdu Kanghong Pharmaceutical Group's (SHE:002773) unit, Chengdu Hongji Biotechnology, will conduct clinical trials on the KH658 ophthalmic injection after receiving approval from China's National M

MT NewswiresApr 29 18:46

Kanghong Pharmaceutical (002773.SZ): Clinical trial of KH658 ophthalmic injection approved

According to Zhitong Finance App, Kanghong Pharmaceutical (002773.SZ) issued an announcement. On April 28, 2024, the KH658 ophthalmic injection declared by the company's subsidiary Chengdu Hongji Biotechnology Co., Ltd. obtained an approval notice for drug clinical trials from the China Drug Administration and agreed to carry out phase I/II clinical trials. According to reports, KH658 ophthalmic injection is the second product of Hongji Biotech to be approved for clinical trials in China and the US at the same time. It uses a novel adeno-associated virus with independent intellectual property rights and a cell-specific receptor design as a delivery carrier. It is easy to administer, is safe, and has cell-mediated efficacy

Zhitong FinanceApr 29 08:05

Express News | Kanghong Pharmaceutical: The subsidiary obtained permission from the US FDA to conduct clinical trials

BreakingsApr 29 08:00

Express News | Kanghong Pharmaceutical: Net profit from mother in the first quarter was 374 million yuan, up 33.72% year-on-year

BreakingsApr 24 19:26

Kanghong Pharmaceutical's Mosapride Citrate Tablets Wins Centralized Procurement Bid

Chengdu Kanghong Pharmaceutical Group's (SHE:002773) mosapride citrate tablets were selected for a centralized procurement bid of an alliance of 13 Chinese provinces, according to the company's disclo

MT NewswiresApr 17 12:00

Express News | Kanghong Pharmaceutical: Selected from the company's products, mosapride citrate tablets, 13 provincial (district, military) coalition drug centralized volume procurement

BreakingsApr 16 20:32